Introduction. Combinations of gefitinib and radiotherapy have been observed to have synergistic and anti-proliferative effects on lung cancer in vitro. In the clinical setting, patients who presented with respiratory difficulties such as superior vena cava syndrome (SVCS), radiotherapy should be given immediately to address the emergency while waiting for the results of epidermal growth factor receptor (EGFR) mutation test. However, there has been no study that described the role of radiotherapy in Indonesian patients with EGFR-mutant lung adenocarcinoma.
INTRODUCTION
Primary lung cancer is a malignant disease originated from the bronchial epithelial cell [1, 2] . Globally, lung cancer is a major newly diagnosed cancer disease, comprising 12.4%, and responsible for 17.6% of cancer-related mortality [3] . Data from the Department of Anatomical Pathology of the Persahabatan Hospital, Jakarta, Indonesia, showed that lung cancer prevalence was more than 50% of all diagnosed cancer. Report from Dharmais Indonesian Cancer Hospital, Jakarta, Indonesia, from the years [2003] [2004] [2005] [2006] [2007] showed that tracheal, bronchus and lung cancer were the second most prevalent malignancy-related morbidity in male (13.4%) after nasopharyngeal cancer (13.63%) and were the most common-related mortality in male (28.94%) [1, 2] . This disease was also becoming more prevalent in Asian population [4, 5] .
In July 2002, gefitinib as an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) has been approved in the treatment of non-small cell lung cancer (NSCLC) in Japan [6] . Pre-clinical data suggest that blockade of EGFR signaling pathway will enhance the radiation-induced cytotoxic effect [7] . It has been reported that the combination of gefitinib and radiotherapy resulted in synergistic anti-proliferative effect against NSCLC cells in vitro [8] . However, there has been no report about the efficacy and toxicity of radiotherapy in Indonesian EGFR-mutant lung cancer patients. The purpose of this study is to address the efficacy and toxicities, both hematologic and non-hematologic, of combining gefitinib and radiotherapy in lung adenocarcinoma patients with EGFR sensitizing-mutation.
MATERIALS AND METHODS
This is an analytical and observational retrospective cohort based on patient medical records who meet the inclusion criteria. The inclusion criteria were lung adenocarcinoma patients with sensitizing EGFR mutation, who received gefitinib minimally 2 months and were treated with radiotherapy as minimal as 30 Gy in the primary tumor. In a sequential manner, the radiotherapy was given 1 month after progressive disease during gefitinib treatment. The exclusion criterion was subject who was unable to be traced after diagnosis has been established. This study was conducted at the Persahabatan Hospital, Jakarta, Indonesia, from May 2016 till March 2017 and has been granted ethical clearance by the Institutional Board Review (IRB) of the Faculty of Medicine Universitas Indonesia (No. 435/UN2.FI/ETIK/2-16) and Persahabatan Hospital (No. 124/KEPK-RSUPP/08/2016). EGFR mutation analysis was performed by using Polymerase chain reaction-based High resolution Melting (PCR-HRM). Therapeutic response was assessed based on the Response Evaluation Criteria in Solid Tumors (RECIST) that combine subjective, semiobjective and objective assessment.
Statistical analysis was performed on parametric and non-parametric data. The parametric test was performed on data that presented as interval scale, ratio and normally distributed, meanwhile non-parametric test was employed in nominal and ordinal data or was not normally distributed. The statistical testing was done by Chi-square test. Survival curves were generated by Kaplan-Meier technique. Significant association was established with P-value below 0.05. SPSS version 20 (IBM Corp, Armonk, NY, USA) was used in the statistical analysis.
RESULTS
Initially, there were totally 1359 patients who received radiotherapy in the Persahabatan Hospital, Jakarta, Indonesia, from January 2013 until December 2016 and 593 subjects were lung cancer patients. The number of lung adenocarcinoma patients who received targeted therapy combined with radiotherapy was 31 subjects. Seventeen (58.1%) patients received 30 Gy, 9 (25.8%) patients received 40 Gy, and 5 (16.1%) patients received 50 Gy. Additional radiotherapy was given in a concurrent manner in 26 subjects (83.9%), sequential manner in 5 subjects (16.1%) and there was no alternating manner. Subject gender was equally distributed between male and female and most of these subjects were non-smokers. The median age was 56 years old, with male slightly younger than female. Most of the male subjects were on performance status 2, while most of the female subjects were on performance status 1. The majority of the studied patients were on Stage 4B, the most common complication for male and female were SVCS and clinically progressive disease, respectively. The 'other' clinical condition for radiotherapy includes patients who, while waiting for the EGFR mutational analysis results, had a subjective symptom of chest pain. The most common EGFR mutation was Exon 21 L858R. The subject characteristics are described in Table 1 .
First, we analyzed the association between therapeutic response and the type of mutation. As described in Table 2 , there was a tendency that patients with Exon 19 deletion have more favorable outcome compared to other type of mutations, although it did not reach a statistically significant threshold (P = 0.07).
We postulated that patients with superior vena cava syndrome (SVCS) would have the benefit from radiotherapy as this would abate the immediate threat. We then compared the clinical response between SVCS subjects and those with other conditions. As shown in Table 3 , SVCS patients had a quite similar total clinical response (sum of complete response, partial response, and stable disease) compared to non-SVCS patients (81.8% vs. 80%, respectively).
Next, we analyzed the association between therapeutic response and the time of radiotherapy. In Table 4 , both concurrent and sequential radiotherapy resulted in partial response and/or stable disease in half of the subjects and there was no significant association between clinical response and the time of radiotherapy. We then analyzed the association of EGFR mutation type with the PFS (Fig. 2A) and OS (Fig. 2B) 6 -1401.4) . In this study, there were 3 (9.7%) patients who remained alive at the end of the study. The hematological and non-hematological toxicity among subjects who received a combination of gefitinib and radiotherapy are described in Table 5 and Table 6 , respectively. Most of the male and female subjects had grade 1 -2 anemia, while 1 male subject had grade 3 -4 leucopenia, another had grade 1 -2 thrombocytopenia, and a third presented with grade 3 -4 thrombocytopenia. In terms of non-hematological toxicities, there were some patients with grade 1 -2 skin rash, diarrhea, and paronychia. 
DISCUSSION
The role of radiotherapy in the treatment of advanced NSCLC with sensitizing EGFR mutation is a major issue and still to be clarified. In a previous study involving inoperable NSCLC subjects, EGFR-TKI had a better time-to-partial response than the radiotherapy in term of tumor shrinkage, meanwhile, the radiotherapy as an add-on therapy remains elusive [9] . This is the first study to elucidate the efficacy and toxicities of combining gefitinib and radiotherapy among Indonesian lung cancer patients with EGFR mutation. Demographic characteristic distribution of gender in both groups showed that there are nearly equal proportions of male and female. This is consistent with the previous study by Yahya et al. who reported EGFR-mutant non-squamous NSCLC were distributed between male 51.6% and female 49.4% [10] . The median age of subjects in the current study was 56 years old. However, a study by Chen et al. found the average of NSCLC patients in their study was 65 years old [11] . We observed that most of the studied subjects were Stage IV, followed by Stage IIIB and IIIA, meanwhile Xu et al. stated in their findings that patients with advanced stage disease of lung adenocarcinoma such as IIIB and IV have a chance of receiving benefit from concurrent radiotherapy and gefitinib [12] . The number of lung adenocarcinoma patients who smoke was smaller compared to those who reported not smoking (12.9% vs. 87.1%, respectively). These results are in line with the PIONEER study which demonstrated that EGFR mutation in lung adenocarcinoma was prevalent in the Asian population, female and non-smokers [13] .
There were 3 groups of clinical conditions who received the combination of gefitinib and radiotherapy: superior vena cava syndrome (SVCS); clinically progressive disease, and other conditions. In one report involving 81 SVKS patients hospitalized from 1983 to 1996, from 77 cancer-diagnosed cases, 76% among them were lung cancer cases [14] . Moreover, Mose et al. reported that among 35 SVCS patients, 20 patients were NSCLC, 12 patients were small cell lung cancer [15] . Radiation therapy combined with continuing EGFR-TKI led to a long PFS and OS in EGFR-mutant lung adenocarcinoma patients who suffered from local progression after initial response to EGFR-TKI [16, 17] . However, the therapeutic role of radiotherapy alone in these populations remains to be addressed.
Based on RECIST criteria, among lung adenocarcinoma patients who received additional radiotherapy on EGFR-TKI treatment, 51.6% had progressive disease (PD), 29% had stable disease (SD) and no patients with complete response (CR). However, the total clinical response (CR+PR+SD) in the study was good enough, nearly 50%. A previous study by Levy et al. in lung adenocarcinoma patients treated with gefitinib 4 weeks after radiotherapy, in the RECIST assessment they found PD was 44%, SD 38% and PR19% [18. A study by Chen et al. also observed that using RECIST criteria, the PD was the most common finding [11] .
This study found good total clinical response for radiotherapy in lung adenocarcinoma patients with exon 19 deletional mutation followed by exon 21 mutation of L861Q and L858R. This result is consistent with a study conducted in China in which combination of radiotherapy and EGFR-TKI in EGFR-mutant NSCLC patients resulted longer overall survival in the group of exon 19 deletional mutation compared to exon 21 L858R mutation [19] .
Progression-free survival (PFS) was determined from the day of starting treatment until progressive disease or patient died or during the last follow-up there was no PD, then it will be considered as PD and the study will be ended. In this study, the median PFS of all subjects was 185 days. Levy et al., in their phase 2 clinical trial, evaluated the efficacy of 250 mg/day of gefitinib combined with thorax radiotherapy (66 Gy in 6.5 weeks, 2 Gy/day, 5 fraction/ week) followed by chemotherapy and vinorelbine as first-line treatment in patients with stage IIIB NSCLC non-selected based on EGFR mutation status [18] . They found the PFS was 5 months. Our mean PFS in this study was 265.65 days (±9) and this is similar with the study by Chen et al. who observed that the mean PFS was 9 months [11] .
The median OS in this study was 300 days (range 83 -1174 days). Another study of combining gefitinib and radiotherapy showed the median OS was 11 months and 31% of patients survived during the end of study [18] . Moreover, in a study involving a cohort of 28 lung adenocarcinoma patients, the OS was 8 months [11] .
Side effects of combining radiotherapy and other modalities including molecular targeted therapy remain partially unresolved with several cases of high toxicity in the form of radiation pneumonitis which led to premature end of the study [20] . Toxicities that may occur from gefitinib treatment consist of hematologic (anemia, leukopenia, thrombocytopenia) and non-hematologic such as gastrointestinal disturbance (nausea, vomiting and diarrhea), skin problems (rash, itchy, acne and xerotic skin), alopecia, neuropathic disorder, paronychia, interstitial lung disease (ILD) and pain that have a degree according to WHO criteria [2, 6] . We found skin rash, diarrhea and paronychia as non-hematologic toxicities, while anemia, leucopenia and thrombocytopenia as hematologic toxicities. A study by Kris et al. showed among NSCLC patients who received a combination of gefitinib 250 mg and additional radiotherapy, 62% had a skin disorder and 57% had diarrhea as their non-hematologic toxicities [21] . Another study found that most frequent toxicities of the combination of radiotherapy and gefitinib were gastrointestinal disorder 81%, itchy 81%, respiration disorder 50% [18] .
The main limitation of the current study was the nature of medical record-derived data as the cohort of retrospective observational analysis. Therefore, data relied on the completeness of the medical record. There were some incomplete data on the medical recorded during sampling.
CONCLUSION
To the best of our knowledge, this study is the first to report the efficacy and toxicities of combining radiotherapy and gefitinib in Indonesian patients with lung adenocarcinoma harboring sensitizing EGFR mutation. 
